| Recruiting | REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial NCT06650579 | Emory University | Phase 3 |
| Recruiting | Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Ca NCT06389786 | Mayo Clinic | N/A |
| Recruiting | Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Pr NCT05398302 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Recruiting | Vitamin D for Prostate Endocrine Therapy NCT05838716 | University of Rochester | Phase 3 |
| Recruiting | Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prost NCT05946213 | NRG Oncology | Phase 3 |
| Recruiting | Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side NCT05722288 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Pr NCT05241860 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Withdrawn | Gallium-68 PSMA-11 PET in Participants With Prostate Cancer NCT05034562 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer NCT05113537 | Vadim S Koshkin | Phase 1 / Phase 2 |
| Recruiting | Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoC NCT05168618 | University of Utah | Phase 2 |
| Terminated | Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer NCT05037500 | Roswell Park Cancer Institute | Phase 1 |
| Terminated | Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patient NCT04616547 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate C NCT04455750 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Completed | Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion NCT04976257 | Ryan Kohlbrenner, MD | EARLY_Phase 1 |
| Active Not Recruiting | 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer NCT04716725 | Thomas Hope | Phase 2 |
| Recruiting | High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma NCT04945642 | Jonsson Comprehensive Cancer Center | N/A |
| Terminated | 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression NCT04927663 | Rahul Aggarwal | Phase 1 |
| Recruiting | Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Loc NCT04947254 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer NCT04754425 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Ca NCT04915508 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Terminated | 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Prog NCT04928820 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Recruiting | Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prosta NCT04734730 | City of Hope Medical Center | Phase 2 |
| Withdrawn | Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer NCT03709550 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Recruiting | Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, t NCT04693377 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer NCT04471974 | Rahul Aggarwal | Phase 2 |
| Active Not Recruiting | Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low NCT04513717 | NRG Oncology | Phase 3 |
| Terminated | Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing Definitive Radiation The NCT04927559 | University of Southern California | — |
| Withdrawn | Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemica NCT04585932 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers NCT04388852 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treatin NCT03649841 | University of Washington | Phase 2 |
| Terminated | Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer NCT03999515 | University of Washington | Phase 2 |
| Recruiting | Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery NCT04134260 | NRG Oncology | Phase 3 |
| Terminated | Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Re NCT04279561 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Recruiting | Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor M NCT05054296 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes NCT04501913 | City of Hope Medical Center | — |
| Completed | Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Thera NCT04037254 | NRG Oncology | Phase 1 / Phase 2 |
| Active Not Recruiting | PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer NCT03873805 | City of Hope Medical Center | Phase 1 |
| Completed | Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer NCT03751436 | Roswell Park Cancer Institute | Phase 1 |
| Completed | A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors NCT03784677 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate C NCT03821792 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study NCT03707574 | National Cancer Institute (NCI) | — |
| Completed | Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer NCT04067960 | Mayo Clinic | EARLY_Phase 1 |
| Active Not Recruiting | Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer NCT03987386 | M.D. Anderson Cancer Center | Phase 3 |
| Withdrawn | Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response NCT03581500 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prosta NCT03678025 | SWOG Cancer Research Network | Phase 3 |
| Active Not Recruiting | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutati NCT03218826 | National Cancer Institute (NCI) | Phase 1 |
| Completed | 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer NCT04050215 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Terminated | Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant NCT03360721 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced NCT03217747 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prost NCT03204812 | M.D. Anderson Cancer Center | Phase 2 |